EYPT - EyePoint inks lease for setting up of new manufacturing facility in Massachusetts

• EyePoint Pharmaceuticals ( NASDAQ: EYPT ) said it signed a lease agreement to design and construct a 40K square-foot manufacturing facility in Northbridge, Massachusetts for its programs, including EYP-1901 and Yutiq.
• The facility, which will be Good Manufacturing Practice (GMP) compliant, will be constructed and managed by V.E. Properties IX and is expected to be operational in H2 2024.
• EyePoint CFO George Elston said that the company will get ~$1.9M in state and local tax incentives as part of its commitment to the facility and the local jobs that it will create.
• "This new facility provides us with significant manufacturing capacity to accelerate the clinical development and future commercial production for EYP-1901, as well as support global demand for our U.S. FDA and China NMPA approved therapy, YUTIQ," said EyePoint CEO Nancy Lurker.
• The company noted that rent will begin in H2 2024.
• Yutiq is an intravitreal implant for treating chronic non-infectious uveitis affecting the posterior segment of the eye.

For further details see: